Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Foreign ingredient petitions

This article was originally published in The Tan Sheet

Executive Summary

FDA will "give priority" to reviews of time and extent applications (TEAs) submitted by firms that previously petitioned to include foreign-marketed ingredients in OTC monographs, agency reiterates in letters to ingredient suppliers, their attorneys. As outlined in Jan. 23 final reg, petitions must be converted to TEAs "within 120 days" of rule's publication (1"The Tan Sheet" Jan. 28, 2002, p. 3). Letters to Ciba Specialty Chemicals, EM Industries, BASF counsel, Haarmann & Reimer counsel, dated from April 19 to April 25, advise firms that FDA will not take "further action" on their respective petitions for sunscreen ingredients. Similar letters also sent to P&G (antiseptics), European-American Phytomedicines Coalition (valerian/sleep aid, ginger/antiemetic petitions) and American Vitamin Products (ginger)...

You may also be interested in...

Extended TEA deadlines

FDA grants 90-day extension, until Aug. 21, for priority review submission of "time and extent" applications based on previously filed citizen petitions to include foreign-marketed ingredients in OTC monographs. Agency's June 20 letters to various firms recognize several factors limiting companies' abilities to complete applications by original May 23 deadline, including age of original petitions, foreign locations of parent companies. Merck KGaA, BASF, P&G, European-American Phytomedicines Coalition were among petitioners notified about extension; ingredients at issue include sunscreens, antiseptics, ginger, valerian (1"The Tan Sheet" May 6, 2002, In Brief)...

OTC “Time & Extent” Requirements Reduced For Extensively Marketed Drugs

Sponsors of OTC drugs with extensive foreign marketing experience need not provide detailed information from each country in requesting the drug or "condition" be considered for OTC monograph eligibility in the U.S., FDA says

Sarepta's DMD Gene Therapy: Durable Responses After Two Years

Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts